It has been demonstrated that the phar macological potencies of some benzo diazepines (BZs) highly correlate with their binding affinities for 3H-BZ sites in the brain (1) (2) (3) (4) . In particular, anticonvulsant activity, antiaggressive activity and muscle-relaxant activity were closely correlated with the inhibition of 3H-diazepam binding (2) . These correlations, however, do not always demonstrate the mechanisms of all typical and atypical BZ-induced pharmacological effects.
Recently, several papers have described the existence of multiple BZ receptors (5) (6) (7) (8) . Furthermore, the distribution of BZ receptor subtypes in the central nervous system (CNS) is heterogeneous and the proportion of BZ receptor subtypes does differentially localize in some brain regions (see 9). This heterogeneity in distribution may explain the multiple BZ pharmacological effects. For example, the triazolopyridazine CL 218,872 has a preferential affinity for the so-called BZ type 1 receptors in vitro and also may possess antianxiety properties with little sedation (5, 9, 10) . This drug has also higher affinity binding sites in the cerebellum than in the cortex (3, 8, 9 did not demonstrate any significant differ ences. However, the binding capacities of each regions did show different values. The Bmax of both the cortex and cerebellum were similar and higher than that of the hip pocampus.
In the spinal cord, the binding capacity was about 8 and 10 times less than that of the cerebellum and cortex, respec tively. In contrast, the Bmax of 3H-Ro 5 4864 binding sites in the spinal cord was more than 2 times of that in the cerebellum, although the Kd values of 3H-Ro 5-4864 binding sites in both the regions did not appear to show significant differences. Additionally,
the Kd values of 3H-FLU binding were significantly different from that of 3H-Ro 5-4864 in both the cerebellum and the spinal cord. In both regions, 3H-FLU binding sites had much higher affinity than 2H-Ro 5-4864 binding sites .
Kd values were used for measuring K; values of each BZ to both 3H-ligands in each region (Tables 2 and 3 ). The inhibitory effects of typical and atypical BZs on the BZ-type 1 and/or 2 receptors are shown in Table 2 . In agreement with previous reports, the proportion of BZ type 1 /2 in the cerebellum, cortex, hippocampus and spinal cord were observed at the ratios of 90/10, 60/40, 40/60 and 10/90, respectively (9, 16, 17, 21). The K; value of CL 218,872, which acts preferentially on the BZ-type 1 receptor in each region supports these ratios. The lowest K; value of CL 218,872 to 3H-FLU was demonstrated in the cerebellum, and this K; value was about four, nine and fifteen times less than in the cortex, hippocampus and spinal cord, respectively. However, the K; values of other BZs to 3H-FLU did not appear to correlate with the different pro portion of BZ-type 1 and 2 receptors in each region, unlike CL 218,872. The typical BZs, except for Ro 5-4864, showed similar results in each region.
In the group of atypical BZs, the K; value of each drug did not demonstrate definite differences between the four regions except for CL 218,872.
However, the K; values of zopiclone in the cerebellum was about two times lower than that in the hippocampus. Between the cortex and spinal cord, the affinities of suriclone showed about a two fold difference. In addition, Ro 5-4864, a peripheral type BZ, demonstrated a very high K; value (about 4 iiM) in the spinal cord, although this drug had no affinity for 3H-FLU binding sites in the cerebellum, cortex and hippocampus.
Among the drugs tested, brotizolam showed the highest affinity in each brain region, and these affinities were about one tenth of those of diazepam. As shown in Fig. 1 , the displacement curve of all drugs tested to 3H-FLU binding sites demon strated the same shape, comparing the cerebellum and spinal cord. Similar results were shown in other brain regions (i.e., hippocampus and cortex), although the inhibitory curve of suriclone to 3H-FLU binding in the cortex appeared much steeper between 5 nM and 10 nM than in the spinal cord (these data are not shown). Table 3 demonstrates the K; values of in addition to brotizolam, demonstrated a high affinity to PBS. These K; values were almost in the same range and did not appear to be different between the spinal cord and cerebellum.
All tested drugs were classified according to their selectivity for the BZ-type 1 and/or 2 receptor and the "central" / "peripheral" type ( in 3H-FLU binding was increased by muscimol, and CL 218,872 also showed the hypnotic action in mice, although the ED50 for the hypnotic dose of this drug was three times greater than that of flurazepam. They concluded that the hypnotic action of BZs involves a supramolecular structure composed of both BZ and GABA receptors, although they failed to demonstrate the hypnotic effects of nitrazepam in mice.
As described in the introduction, it is well documented that the anti-convulsant ac tivities of BZs seemed to correlate well with their receptor binding affinities, unlike the relation between hypnotic action and binding affinities (1) (2) (3) 25) . These different obser vations suggest that the hypnotic and anti convulsant potencies of BZs do not share the same mechanism (see 25). Our results also failed to show the correlation between hypnotic drugs and BZ-type 1 /2 selectivity, although each drug appeared to show a different potency to inhibit the 3H-FLU binding sites in each brain region (Table 2) . According to our previous results, brotizolam had much higher affinity to BZ-type 2 than BZ-type 1 (26). However, the earlier report is not in agreement with our current results. This discrepancy cannot be explained in more detail at present time, but it might be caused by the different tissues used (i.e., neonatal rat cortex and adult spinal cord). The number of BZ-type 2 receptors was about two times greater in the neonatal rat than in the adult spinal cord (27). It may also be more difficult to detect small alterations in adult spinal cord than in neonatal rat cortex. However, as in our previous study (4), brotizolam showed the highest affinity to 3H FLU binding sites in the tested drugs. Additionally, the Hill coefficient (data are not show) and the slope of the displacement curve of brotizolam (Fig. 1) (Table 2 ), compared to several "classical" and "new" BZs (4). It is difficult to explain the function of this drug in relation to PBS in the spinal cord and cerebellum at present. Brotizolam seems to have some effects similar to Ro 5-4864, PK 11195 and diazepam such as the enhancement of 3H-methyl group incorporation into phosphatidylcholine and/or the antior pro-convulsive actions of maximum electroshock-induced seizure (6, 31). In our results, there was significantly more binding of Ro 5-4864 in the spinal cord than in the cerebellum. These results support the previous reports on the different localization of "PBS" in not only the brain but also in the spinal cord.
Our results suggest the following con clusions: 1) With respect to the ratio of the K; value of 3H-FLU in the spinal cord (type 2/type 1 =90/10) to the K, value of 3H-FLU in the cerebellum (type 2/type 1 =10/90), CL 218,872 appears to be a selective ligand of the BZ type 1 receptor.
Other BZs, however, appeared to have similar affinities for both BZ receptor subtypes (Fig. 4) . 2) Not only but diazepam and brotizolam demonstrated the characteristics of "peripheral" type BZ ligands. The K; value of brotizolam to the 3H-Ro 5-4864 binding sites in the spinal cord showed results similar to that of diazepam, but the ratio of "central" type BZ receptors to the peripheral" type of brotizolam was 10 times less than that of diazepam (Fig. 4). 3) In the typical BZs, nitrazepam was evaluated like diazepam, to have the same affinity for both BZ type 1 and 2 receptors, but it had no affinity for PBS. 4) The inhibitory effect of suriclone, an atypical BZ, to 3H-Ro 5-4864 binding sites was not determined, although this drug has the strong affinity to BZ type 2 receptors.
